Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Enzymes in secondary pharmacology screening panels: is there room for improvement?

Nature Reviews Drug Discovery volume 24, pages 480–481 (2025)Cite this article

Subjects

Access through your institution
Buy or subscribe

A recent article by Brennan and colleagues (Nat. Rev. Drug Discov. 23, 525–545; 2024)1 presents the findings of the largest collaborative effort among leading pharmaceutical companies on the application of secondary pharmacology screening to identify off-target activities of drug candidates, showing that wider adoption of standardized selectivity profiling has positively affected the safety of newer small-molecule drugs. The authors recommend an expanded panel of off-targets that is partly based on two earlier panels proposed by Bowes et al.2 and Lynch et al.3. We applaud Brennan and colleagues for completing this important collaborative work and expect their study will impact drug development substantially. Nevertheless, we want to use this opportunity to discuss an overlooked issue of non-kinase enzyme representation in the screening panels recommended thus far.

The three noted panels include a partially overlapping set of targets associated with well-characterized safety concerns and are comprised of 44 (Bowes-44)2, 70 (Lynch-70)3, and 77 (Brennan-77)1 targets, covering the main pharmacological classes. Regarding enzymes, these panels only include 6 to 9 non-kinase enzymes, comprising 12% of all targets in the latest Brennan-77 panel (Fig. 1c). Since enzymes are a leading category for the ‘to-be’ and currently approved drugs, it is surprising that the share of enzymes in selectivity panels remains so limited. This underrepresentation is further highlighted by a recent study from Amgen showing the involvement of enzymes in about one-third of drug-related adverse events (23% non-kinase enzymes and 10% kinases)4. Similarly, an FDA study on the secondary pharmacology of investigational new drugs concluded that enzymes are tested less frequently than other targets despite comparable or higher hit rates5.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Enzymes as drug targets and in secondary pharmacology screening panels.

References

  1. Brennan, R. J. et al. The state of the art in secondary pharmacology and its impact on the safety of new medicines. Nat. Rev. Drug Discov. 23, 525–545 (2024).

    Article  CAS  PubMed  Google Scholar 

  2. Bowes, J. et al. Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nat. Rev. Drug Discov. 11, 909–922 (2012).

    Article  CAS  PubMed  Google Scholar 

  3. Lynch, J. J., Van Vleet, T. R., Mittelstadt, S. W. & Blomme, E. A. G. Potential functional and pathological side effects related to off-target pharmacological activity. J. Pharmacol. Toxicol. Methods 87, 108–126 (2017).

    Article  CAS  PubMed  Google Scholar 

  4. Deaton, A. M. et al. Rationalizing secondary pharmacology screening using human genetic and pharmacological evidence. Toxicol. Sci. 167, 593–603 (2019).

    Article  CAS  PubMed  Google Scholar 

  5. Scott, C., Dodson, A., Saulnier, M., Snyder, K. & Racz, R. Analysis of secondary pharmacology assays received by the US Food and Drug Administration. J. Pharmacol. Toxicol. Methods 117, 107205 (2022).

    Article  CAS  PubMed  Google Scholar 

  6. Paolini, G. V., Shapland, R. H. B., Van Hoorn, W. P., Mason, J. S. & Hopkins, A. L. Global mapping of pharmacological space. Nat. Biotechnol. 24, 805–815 (2006).

    Article  CAS  PubMed  Google Scholar 

  7. Owens, R. E. & Oliphant, C. S. Angioedema spotlight: A closer examination of sacubitril/valsartan safety results. J. Am. Board Fam. Med. 30, 556–557 (2017).

    Article  PubMed  Google Scholar 

  8. Smit, I. A. et al. Systematic analysis of protein targets associated with adverse events of drugs from clinical trials and postmarketing reports. Chem. Res. Toxicol. 34, 365–384 (2021).

    Article  CAS  PubMed  Google Scholar 

  9. Kelly, M. P. et al. Cyclic nucleotide phosphodiesterases as drug targets. Pharmacol. Rev. https://doi.org/10.1016/j.pharmr.2025.100042 (2025).

    Article  PubMed  Google Scholar 

  10. Bendels, S. et al. Safety screening in early drug discovery: An optimized assay panel. J. Pharmacol. Toxicol. Methods 99, 106609 (2019).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Current research in the Karamyan laboratory focusing on peptidases is supported by an NIH research grant (1R01NS106879).

Author information

Authors and Affiliations

  1. Department of Foundational Medical Studies, William Beaumont School of Medicine, Oakland University, Rochester, MI, USA

    Monika Maciag & Vardan T. Karamyan

Authors
  1. Monika Maciag
    View author publications

    Search author on:PubMed Google Scholar

  2. Vardan T. Karamyan
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Vardan T. Karamyan.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Related links

Pharos: https://pharos.nih.gov

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Maciag, M., Karamyan, V.T. Enzymes in secondary pharmacology screening panels: is there room for improvement?. Nat Rev Drug Discov 24, 480–481 (2025). https://doi.org/10.1038/s41573-025-01173-w

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41573-025-01173-w

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research